SUWANEE, Ga., March 06, 2020 -- Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) reported today its financial results for the fourth quarter (Q4) and year.
SUWANEE, Ga., May 15, 2020 -- Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) reported today its financial results for the first quarter (Q1) ended.
SUWANEE, Ga., Nov. 14, 2019 -- Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) reported today its financial results for the third quarter (Q3) and nine.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) * Allogene Therapeutics Inc (NASDAQ: ALLO)(reacted to ASCO abstract) * Altimmune Inc (NASDAQ: ALT)(announced first-quarter results and update to its COVID-19 vaccine program) * BioXcel Therapeutics Inc (NASDAQ: BTAI)( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) * Co-Diagnostics Inc (NASDAQ: CODX) * Myokardia Inc (NASDAQ: MYOK) * Repligen Corporation (NASDAQ: RGEN) * Translate Bio Inc (NASDAQ: TBIO) * VBI Vaccines Inc (NASDAQ: VBIV)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) * Genfit SA (NASDAQ: GNFT) * Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1) * RA Medical Systems Inc (NYSE: RMED)(reacted to first-quarter results) * Recro Pharma Inc (NASDAQ: REPH) * Sensus Healthcare Inc (NASDAQ: SRTS) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONNStocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ:NK) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.The company noted that out of the four patients treated with PD-L1 t-haNK and N-803 under single patient INDs, two were on treatment for the evaluable period. Of these two patients, one reported ongoing, durable, complete response six months after treatment, and one observed response of stable disease. It expects to begin the Phase 2 study in June."Our results from expanded access use of PD-L1 t-haNK in combination with N-803 offer proof-of-concept that, together with these agents, the immune system may play a role to activate robust and durable responses in metastatic cancer patients who have failed all standard-of-care therapies, said Patrick Soon-Shiong, CEO of NantKwest and ImmunityBio.NantKwest stock fell 8.54% to $4.71 in after-hours trading.Phio Presents Encouraging Data For Gene Silencing Platform Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced data analyzing the applicability of the INTASYL platform as a gene silencing technology that offers an alternative or complementary approach to gene editing technologies, such as CRISPR/Cas9, in the treatment of solid tumors.The data presented as a poster at the American Society of Gene and Cell Therapy 23rd Virtual Annual Meeting showed that INTASYL compared favorably to other technologies for improving cells used in adoptive cell therapy for the treatment of solid tumors, especially in cases where permanent gene modification is not required or is undesirable.The stock rose 5.14% to $2.25 in after-hours trading.Earnings Sellas Life Sciences Group Inc (NASDAQ: SLS) reported a first-quarter net loss of 66 cents per share compared to a loss of $11.12 per share last year. Analysts estimated a wider loss of 74 cents per share. Cash and cash equivalents totaled about $6.7 million at the end of March 31, 2020, compared to $2.6 million as of March 31, 2019The stock rallied 13.24% to $3.25 in after-hours trading.Applied DNA Sciences Inc's (NASDAQ: APDN) fiscal year second-quarter revenues fell 29% year-over-year to $552,000. The net loss narrowed from $1.12 per share to 79 cents per share. Analysts, on average, estimated a loss of 77 cents per share on revenues of $950,000.View more earnings on IBBIn after-hours trading, the stock was down 11.77% to $13.42.TFF Pharmaceuticals Inc (NASDAQ: TFFP) reported a first-quarter loss of 20 cents per share compared to a loss of 55 cents per share a year ago. Analysts estimated a loss of 24 cents per share. The stock jumped 17.02% to $5.50 in after-hours trading.Co-Diagnostics reported a strong increase in its first-quarter revenues to $1.55 million from $3,400 a year ago. The loss per share narrowed from 9 cents to 5 cents, in line with estimate.Offering a mid-quarter update for the second quarter, the company said it has manufactured more than 6 million COVID-19 tests to date and has ordered for components for more than 20 million additional tests. The company also said its test kit showed 100% specificity and 100% sensitivity in several independent evaluations.The stock retreated 15.95% to $18.60 in after-hours trading.Offerings TG Therapeutics Inc common stock (NASDAQ: TGTX) priced its upsized underwritten public offering of 8.5 million shares at $18 per share for raising gross proceeds of $153 million. All the shares are being offered by the company. The company expects the offering to close May 19.The stock slipped 2.26% to $19.48 in after-hours trading.Boston Scientific Corporation (NYSE: BSX) priced its public offering of $1.7 billion aggregate principal amount of its senior notes.The public offering consists of $500 million in aggregate principal amount of 1.90% notes due 2025 and $1.2 billion in aggregate principal amount of 2.65% notes due 2030. The company intends to use the net proceeds to repay its debt.Oyster Point Pharma Inc (NASDAQ: OYST) priced its underwritten public offering of 3.75 million shares at $28 per share. All of the shares are being offered by the company. The offering, which is expected to close May 19, is likely to generate gross proceeds of $105 million for the company.The stock was slipping 6.31% to $30.01 in premarket trading Friday.On The Radar PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS) awaits FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.Clinical Readouts Pfizer Inc. (NYSE: PFE) will present at the ASGCT meeting, Phase 1b data for PF-06939926 in Duchenne muscular dystrophy at 10 am ET.Earnings Digirad Corporation (NASDAQ: DRAD) (before the market open) * Zyla Life Sciences (OTC: ZCOR) (before the market open) * PLx Pharma Inc (NASDAQ: PLXP) (before the market open) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP) (before the market open) * Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open)IPO Late clinical-stage oncology-focused Swiss biotech ADC THERAPEUTICS priced its upsized initial public offering of 12,245,631 shares of its common shares at $19.00 per share, above the estimated price range of $16-18. The company expects the offering to generate gross proceeds of $232.7 million. The shares are to be listed on the NYSE under the ticker symbol "ADCT."See more from Benzinga * The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger * The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”), a diversified holding company with three operating divisions: healthcare, building and construction, and real estate and investments, today announced the pricing of an underwritten public offering of 2,225,000 shares of its common stock and warrants to purchase up to 1,112,500 shares of the Company’s common stock (the “common warrants”). Each share of common stock is being sold together with one common warrant to purchase 0.5 shares of common stock at a price of $2.25 per share and common warrant. The common warrants will be immediately exercisable at a price of $2.25 per share of common stock and will expire five years from the date of issuance.
Q4 2019 Digirad Corp Earnings Call
Matt Molchan became the CEO of Digirad Corporation (NASDAQ:DRAD) in 2013. This analysis aims first to contrast CEO...
This month, we saw the Digirad Corporation (NASDAQ:DRAD) up an impressive 46%. But the last three years have seen a...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Q3 2019 Digirad Corp Earnings Call
Q1 2020 Digirad Corp Earnings Call
Shares of Digirad Corp. rocketed 76% in active premarket trading Friday, after the company swung to a fourth-quarter adjusted profit as revenue rose 39%. Trading volume jumped to over 428,000 shares ahead of the open, compared with the full-day average of about 37,000 shares. The company operates three divisions, building and construction, which makes modular housing units, real estate and investments that manages manufacturing plants, and the largest division is healthcare, which designs and makes diagnostic medical imaging products. The company reported a net loss that narrowed to $853,000, or 42 cents a share, from $1.6 million, or 79 cents a share, in the year-ago period. Excluding non-recurring items, such as merger-related expenses, adjusted earnings per share came to 30 cents. Revenue rose to $36.1 million from $25.9 million, boosted by the completion of the acquisition ATRM Holdings Inc., which added its building and construction division, with healthcare revenue grew 6.2%. The only analyst that provided estimates to FactSet was looking for a loss of 4 cents a share on revenue of $35.6 million. The stock has climbed 13.5% over the past three months through Thursday, while the S&P 500 has lost 3.9%.
NEW YORK, NY / ACCESSWIRE / March 6, 2020 / Digirad Corp. (DRAD) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 6, 2020 at 10:00 AM Eastern Time. ...
Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) will release its financial results for the fourth quarter and year ended December 31, 2019 before the market opens on Friday, March 6, 2020. Digirad Corporation is a diversified holding company with three operating divisions: Healthcare, Building & Construction and Real Estate & Investments. Healthcare Division (Digirad Health) designs, manufactures, and distributes diagnostic medical imaging products.
Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) announced today new financing to fund the growth strategy for its Building & Construction division for 2020. In September 2019, Digirad completed the acquisition of ATRM Holdings, Inc. (“ATRM”) and converted from being a healthcare services provider into a diversified holding company (“HoldCo”) operating with three business divisions: Healthcare, Building & Construction, and Real Estate & Investments.
Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) will release its financial results for the first quarter ended March 31, 2020, before the market opens on Friday, May 15, 2020. Digirad Corporation is a diversified holding company with three operating divisions: Healthcare, Building & Construction and Real Estate & Investments. Digirad Healthcare designs, manufactures, and distributes diagnostic medical imaging products.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 752 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
If you're interested in Digirad Corporation (NASDAQ:DRAD), then you might want to consider its beta (a measure of...
Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) announced today updates on its growth and value enhancement initiatives. As announced previously, the Company’s 2020 growth strategy for its Building & Construction division is primarily to expand its commercial construction business in New England.
Market forces rained on the parade of Digirad Corporation (NASDAQ:DRAD) shareholders today, when the covering analyst...